Ana Griciuc

Neuroscience · Life Sciences

14h-index2.5kcitations24works23.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroinflammation and Neurodegeneration Mechanisms(12), Alzheimer's disease research and treatments(11), Retinal Development and Disorders(6), Cellular transport and secretion(3), Endoplasmic Reticulum Stress and Disease(3)

Publications24 total

The gain-of-function TREM2-T96K mutation increases risk for Alzheimer’s disease by impairing microglial function
Neuron·2025· 4 citedOpen Access
Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer’s disease
Neuron·2024· 15 citedOpen Access
Expression-based selection identifies a microglia-tropic AAV capsid for direct and CSF routes of administration in mice
2024Open Access
Gene therapy for CNS disorders: modalities, delivery and translational challenges
Nature reviews. Neuroscience·2024· 73 cited
Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
Frontiers in Pharmacology·2023· 18 citedOpen Access
Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease
Phytomedicine·2022· 8 cited
Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease
Nature·2021· 307 citedOpen Access
Evaluation of Fluorinated Cromolyn Derivatives as Potential Therapeutics for Alzheimer’s Disease
Journal of Alzheimer s Disease·2021· 12 cited
The role of innate immune genes in Alzheimer's disease
Current Opinion in Neurology·2021· 190 citedOpen Access
Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation
Human Molecular Genetics·2020· 116 citedOpen Access
Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis
Scientific Reports·2019· 35 citedOpen Access
TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer’s Disease
Neuron·2019· 373 citedOpen Access
Fluorinated Cromolyn Derivatives for Potential Alzheimer’s Disease Treatment
2019· 2 cited
Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis
Scientific Reports·2018· 92 citedOpen Access
[P4–404]: A NOVEL DRUG‐SCREENING PLATFORM IN MICROGLIAL CELLS IDENTIFIES POTENTIAL AD DRUGS
Alzheimer s & Dementia·2017· 2 cited
Proteomic Survey Reveals Altered Energetic Patterns and Metabolic Failure Prior to Retinal Degeneration
Journal of Neuroscience·2014· 29 citedOpen Access
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Neuron·2013· 1.0k citedOpen Access
Looking into Eyes: Rhodopsin Pathologies in Drosophila
Advances in experimental medicine and biology·2011· 4 cited
ER stress in retinal degeneration: a target for rational therapy?
Trends in Molecular Medicine·2011· 56 citedOpen Access
Towards a Molecular Understanding of Retinal Dystrophies
2011
page 1 of 2Next →

Frequent Co-authors

Rudolph E. Tanzi(14), Luisa Quinti(8), Liviu Aron(6), Marius Ueffing(6), Se Hoon Choi(5), D. McGinty(4), Ruslan I. Sadreyev(4), David R. Elmaleh(4), Angela M. Forte(3), Michel J. Roux(3), Angela Giangrande(3), Doo Yeon Kim(3), Anthony Federico(2), Suzanne E. Hickman(2), Joseph El Khoury(2), Mehdi Jorfi(2), Eloïse Hudry(2), Casey A. Maguire(2), Can Zhang(2), Chongzhao Ran(2)